by Ismail Amin | Sep 29, 2022 | Biotech Bulletin, News
While many biotech and life-science companies have impeccable products and intellectual property pipelines, they are often in need of appropriate capital to execute the company’s mission. There are numerous ways to raise capital, from many different markets (private...
by Ismail Amin | Sep 27, 2022 | News
In a landmark crypto-currency litigation case pending before the US District Court in the Southern District of New York, the Securities and Exchange Commission (“SEC”) brought an action against Ripple Labs, Inc. and its officers (“Ripple”). The crux of the SEC’s...
by Ismail Amin | Aug 24, 2022 | Biotech Bulletin, News
In the second part of the clinical trials series, we examine the duties and obligations of Sponsors and Clinical Research Organizations (CRO) as it relates to the protection of human subjects who participate in clinical trials. Generally, a “Human Subject” is an...
by Destiney J. Johnson | Aug 23, 2022 | Business Law, News
Using likeability to a corporation’s advantage increases your chances of trial success. First Impressions are Everything We have all heard the expression, “You only get one chance to make a good first impression.” In the legal context, that popular...
by Ismail Amin | Aug 15, 2022 | Biotech Bulletin, News
In the selection of a Clinical Research Organization (CRO), the Sponsor must ensure that the CRO has careful policies and procedures in place to safeguard protected patient information. Also, Sponsors should evaluate their own privacy protection policies and SOPs in...
by Ismail Amin | Jul 25, 2022 | Biotech Bulletin, News
FDA issues guidance and recommendations for New Drug Applications (NDA) and Biologic Laboratory Applications (BLA) which implicate oncology therapies and warrant Real time Oncology Review (RTOR). On July 25, 2022, the FDA, by and through the Oncology Center for...
